European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
Claus Garbe(University Children's Hospital Tübingen), Paul Lorigan(University of Manchester), Nicole W.J. Kelleners-Smeets(Maastricht University Medical Centre), Véronique Bataille(King's College London), Ricardo Vieira(Hospitais da Universidade de Coimbra), Bodhan Lytvynenko(Shupyk National Healthcare University of Ukraine), D. Moreno‐Ramírez(Hospital Universitario Virgen Macarena), Célèste Lebbé(Inserm), Petr Arenberger(Charles University), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Roland Kaufmann(Jet Company (Czechia)), Axel Hauschild(Kiel University), Josep Malvehy(Instituto de Salud Carlos III), Christoph Höeller(Medical University of Vienna), Maria Concetta Fargnoli(University of L'Aquila), Teresa Amaral(University of Tübingen), Aimilios Lallas(Aristotle University of Thessaloniki), Lars Bastholt(Odense University Hospital), Nicole Basset‐Séguin(Inserm), Jean‐Jacques Grob, V. del Mármol(Université Libre de Bruxelles), Alexander C. J. van Akkooi(The University of Sydney), Paul Nathan(Mount Vernon Cancer Centre), Iris Zalaudek(University of Trieste), Ana‐Maria Forsea(Carol Davila University of Medicine and Pharmacy), Alexander J. Stratigos(National and Kapodistrian University of Athens), Giovanni Pellacani(Sapienza University of Rome), Ketty Peris(Università Cattolica del Sacro Cuore), Brigitte Dréno(Inserm)
Cited by 287
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k